Literature DB >> 17223873

Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy.

C M Perrett1, J M McGregor, J Warwick, P Karran, I M Leigh, C M Proby, C A Harwood.   

Abstract

BACKGROUND: Organ transplant recipients (OTR) are at high risk of developing nonmelanoma skin cancer and premalignant epidermal dysplasia (carcinoma in situ/ Bowen's disease and actinic keratoses). Epidermal dysplasia is often widespread and there are few comparative studies of available treatments.
OBJECTIVES: To compare topical methylaminolaevulinate (MAL) photodynamic therapy (PDT) with topical 5% fluorouracil (5-FU) cream in the treatment of post-transplant epidermal dysplasia.
METHODS: Eight OTRs with epidermal dysplasia were recruited to an open-label, single-centre, randomized, intrapatient comparative study. Treatment with two cycles of topical MAL PDT 1 week apart was randomly assigned to one area of epidermal dysplasia, and 5-FU cream was applied twice daily for 3 weeks to a clinically and histologically comparable area. Patients were reviewed at 1, 3 and 6 months after treatment. The main outcome measures were complete resolution rate (CRR), overall reduction in lesional area, treatment-associated pain and erythema, cosmetic outcome and global patient preference.
RESULTS: At all time points evaluated after completion of treatment, PDT was more effective than 5-FU in achieving complete resolution: eight of nine lesional areas cleared with PDT (CRR 89%, 95% CI: 0.52-0.99), compared with one of nine lesional areas treated with 5-FU (CRR 11%, 95% CI: 0.003-0.48) (P = 0.02). The mean lesional area reduction was also proportionately greater with PDT than with 5-FU (100% vs. 79% respectively). Cosmetic outcome and patient preference were also superior in the PDT-treated group.
CONCLUSIONS: Compared with topical 5-FU, MAL PDT was a more effective and cosmetically acceptable treatment for epidermal dysplasia in OTRs and was preferred by patients. Further studies are now required to confirm these results and to examine the effect of treating epidermal dysplasia with PDT on subsequent development of squamous cell carcinoma in this high risk population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223873      PMCID: PMC2423222          DOI: 10.1111/j.1365-2133.2006.07616.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  45 in total

Review 1.  Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source.

Authors:  S Varma; H Wilson; H A Kurwa; B Gambles; C Charman; A D Pearse; D Taylor; A V Anstey
Journal:  Br J Dermatol       Date:  2001-03       Impact factor: 9.302

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells.

Authors:  P Uehlinger; M Zellweger; G Wagnières; L Juillerat-Jeanneret; H van den Bergh; N Lange
Journal:  J Photochem Photobiol B       Date:  2000-01       Impact factor: 6.252

4.  Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate.

Authors:  Q Peng; A M Soler; T Warloe; J M Nesland; K E Giercksky
Journal:  J Photochem Photobiol B       Date:  2001-09-15       Impact factor: 6.252

5.  5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters.

Authors:  E Rud; O Gederaas; A Høgset; K Berg
Journal:  Photochem Photobiol       Date:  2000-05       Impact factor: 3.421

6.  Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy.

Authors:  C A Morton; C Whitehurst; J V Moore; R M MacKie
Journal:  Br J Dermatol       Date:  2000-10       Impact factor: 9.302

Review 7.  Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group.

Authors:  Colin A Morton; S B Brown; S Collins; S Ibbotson; H Jenkinson; H Kurwa; K Langmack; K McKenna; H Moseley; A D Pearse; M Stringer; D K Taylor; G Wong; L E Rhodes
Journal:  Br J Dermatol       Date:  2002-04       Impact factor: 9.302

8.  Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study.

Authors:  R M Szeimies; S Karrer; S Radakovic-Fijan; A Tanew; P G Calzavara-Pinton; C Zane; A Sidoroff; M Hempel; J Ulrich; T Proebstle; H Meffert; M Mulder; D Salomon; H C Dittmar; J W Bauer; K Kernland; L Braathen
Journal:  J Am Acad Dermatol       Date:  2002-08       Impact factor: 11.527

9.  Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.

Authors:  E Stockfleth; C Ulrich; T Meyer; E Christophers
Journal:  Recent Results Cancer Res       Date:  2002

10.  PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients.

Authors:  Allan Oseroff
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

View more
  24 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

2.  Management of high-risk cutaneous squamous cell carcinoma.

Authors:  Lorraine Jennings; Chrysalyne D Schmults
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

Review 3.  Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients.

Authors:  Haider K Bangash; Oscar R Colegio
Journal:  Curr Treat Options Oncol       Date:  2012-09

4.  [Primary and secondary prevention of skin cancer in organ transplant recipients].

Authors:  A S Lonsdorf; M R Becker; E Stockfleth; K Schäkel; C Ulrich
Journal:  Hautarzt       Date:  2010-03       Impact factor: 0.751

Review 5.  Photodynamic therapy in dermatology: a review.

Authors:  Sonal Choudhary; Keyvan Nouri; Mohamed L Elsaie
Journal:  Lasers Med Sci       Date:  2009-08-05       Impact factor: 3.161

6.  Oral azathioprine leads to higher incorporation of 6-thioguanine in DNA of skin than liver: the protective role of the Keap1/Nrf2/ARE pathway.

Authors:  Sukirti Kalra; Ying Zhang; Elena V Knatko; Stewart Finlayson; Masayuki Yamamoto; Albena T Dinkova-Kostova
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-29

Review 7.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

Review 8.  [New developments in photodynamic therapy].

Authors:  E Kohl; S Karrer
Journal:  Hautarzt       Date:  2013-05       Impact factor: 0.751

Review 9.  Biomodulatory approaches to photodynamic therapy for solid tumors.

Authors:  Sanjay Anand; Bernhard J Ortel; Stephen P Pereira; Tayyaba Hasan; Edward V Maytin
Journal:  Cancer Lett       Date:  2012-07-25       Impact factor: 8.679

10.  Basal cell carcinoma treated successfully with combined CO2 laser and photodynamic therapy in a renal transplant patient: a case report.

Authors:  Kayvan Shokrollahi; Nicholas J Marsden; Iain S Whitaker; William James; Maxwell Sc Murison
Journal:  Cases J       Date:  2009-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.